Table 4.
Summary of preclinical tumour- and kidney-absorbed dose coefficients for TAT. ADC = absorbed dose coefficient. Nephroprotection given as administration of L-lysine before TAT. T:K = tumour-to-kidney ratio.
| Author | Radiopharmaceutical | Tumour Bearing | Cell Line | Nephro-Protection | ADC (Gy/MBq) | T:K | |
|---|---|---|---|---|---|---|---|
| Tumour | Kidneys | ||||||
| Chan [61] | [213Bi]Bi-DOTATATE | + | CA20948 | − | 0.8 | 1.6 | 0.49 |
| + | H69 | − | 0.5 | 2.0 | 0.23 | ||
| Chan [63] | [213Bi]Bi-DOTATATE | + | AR42J | + | 0.7 | 0.6 | 1.18 |
| + | AR42J | − | 0.7 | 1.1 | 0.64 | ||
| − | N/A | + | N/A | 0.5 | N/A | ||
| − | N/A | − | N/A | 1.0 | N/A | ||
| Chapeau [65] | [212Pb]Pb-DOTAM-TATE | + | H69 | − | 26.6 | 140.0 | 0.19 |
| [212Pb]Pb-eSOMA-01 | + | H69 | − | 35.5 | 121.7 | 0.29 | |
| [212Pb]Pb-eSOMA-02 | + | H69 | − | 14.7 | 147.4 | 0.10 | |
| Handula [60] | [225Ac]Ac-DOTA-JR11 | + | H69 | − | 328.5 | 952.6 | 0.34 |
| Lee [46] | [212Pb]Pb-DOTA-TOC | + | AR42J | + | 2.4 | 7.0 | 0.35 |
| [212Pb]Pb-PSC-TOC | + | AR42J | + | 9.2 | 5.4 | 1.70 | |
| [212Pb]Pb-PSC-PEG2-TOC | + | AR42J | + | 12.7 | 6.2 | 2.04 | |
| [212Pb]Pb-PSC-PEG2-TOC | + | AR42J | + | 8.7 | 3.2 | 2.69 | |
| Tafreshi [75] | [225Ac]Ac-DOTATATE | − | N/A | − | N/A | 6.8 | N/A |